In what has come as good news for US-based Forest Laboratories, the organization has been successful in securing an approval for Daliresp (roflumilast) from the US Food and Drug Administration (FDA).

After the initial disapproval in April 2010 by the FDA committee on the basis of insufficient proof, Forest Laboratories applied for clearance for a drug to cure chronic obstructive pulmonary disease (COPD).

Considering the concrete evidence produced by the drug maker, FDA gave a final nod to market the product in US. The drug is expected to be a relief for patients suffering from lung infection as this drug would inhibit the spiraling growth of phosphodiesterase type 4 enzymes.

With this news, millions of people reeling under the consequences of lung disease, including chronic cough and phlegm, would be relieved.

Responding to the FDA decision, a spokesman from the Forest informed that the drug was tested on over 1500 bronchitis patients of age more than 40, and the results were medically approved.

Nevertheless, the drug can be used to cure COPD related diseases, the treatment is not been given a nod for serious cases of primary emphysema. With millions of people, especially people in the later stage, suffering from serious ailments pertaining to smoking, this drug seems to be a savior.